GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EPIRUS Biopharmaceuticals Inc (OTCPK:EPRSQ) » Definitions » 14-Day RSI

EPIRUS Biopharmaceuticals (EPIRUS Biopharmaceuticals) 14-Day RSI : N/A (As of May. 29, 2024)


View and export this data going back to 2005. Start your Free Trial

What is EPIRUS Biopharmaceuticals 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-05-29), EPIRUS Biopharmaceuticals's 14-Day RSI is N/A.

The industry rank for EPIRUS Biopharmaceuticals's 14-Day RSI or its related term are showing as below:

EPRSQ's 14-Day RSI is not ranked *
in the Biotechnology industry.
Industry Median: 44.83
* Ranked among companies with meaningful 14-Day RSI only.

Competitive Comparison of EPIRUS Biopharmaceuticals's 14-Day RSI

For the Biotechnology subindustry, EPIRUS Biopharmaceuticals's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EPIRUS Biopharmaceuticals's 14-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EPIRUS Biopharmaceuticals's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where EPIRUS Biopharmaceuticals's 14-Day RSI falls into.



EPIRUS Biopharmaceuticals  (OTCPK:EPRSQ) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


EPIRUS Biopharmaceuticals  (OTCPK:EPRSQ) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


EPIRUS Biopharmaceuticals 14-Day RSI Related Terms

Thank you for viewing the detailed overview of EPIRUS Biopharmaceuticals's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


EPIRUS Biopharmaceuticals (EPIRUS Biopharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
699 Boylston Street, Eighth Floor, Boston, MA, USA, 02116
EPIRUS Biopharmaceuticals Inc is a global biopharmaceutical company focused on building biosimilar business targeting rare diseases by improving patient access through cost-effective medicines. The product candidates of the company are BOW080 for the potential treatment of ultra-rare blood disorders and BOW070 for the potential treatment of an uncommon lymphoproliferative disorder known as Castleman's disease. The group generally operates through the United States.
Executives
Vincent Aurentz officer: Chief Business Officer C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Thomas A. Shea officer: Chief Financial Officer C/O EPIRUS BIOPHARMACEUTICALS, INC., 699 BOYLSTON STREET 8TH FLOOR, BOSTON MA 02116
Amit Munshi director, officer: Chief Executive Officer C/O EPIRUS BIOPHARMACEUTICALS, INC., 699 BOYLSTON STREET, 8TH FLOOR, BOSTON MA 02116
Scott M Rocklage director, 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Julie Mchugh director C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Mark Corrigan director
Geoffrey M Duyk director 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
J Kevin Buchi director 41 MOORES ROAD, FRAZER PA 19355
Montreux Equity Partners Iv Lp 10 percent owner ONE FERRY BUILDING,, SUITE 255, SAN FRANCISCO CA 94111
5am Ventures Iii, L.p. 10 percent owner 2200 SAND HILL ROAD, SUITE 110, MENLO PARK CA 94025
5am Co-investors Iii, L.p. 10 percent owner 2200 SAND HILL ROAD, SUITE 110, MENLO PARK CA 94025
Andrew J. Schwab 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
John D Diekman 10 percent owner C/O 5 AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Partners Iii, Llc 10 percent owner 2200 SAND HILL ROAD STE 110, MENLO PARK CA 94025
David Bonderman 10 percent owner 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102

EPIRUS Biopharmaceuticals (EPIRUS Biopharmaceuticals) Headlines

From GuruFocus

CEO of Epirus Biopharmaceuticals Buys 10,000 Shares

By Jennifer Chiou Jennifer Chiou 09-23-2015